IP Library Granted Patent US 9,346,851
Granted Patent B2
US 9,346,851 · App. 12/918,678 · Granted May 24, 2016

Chemical modification of proteins

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,346,851
App. No.
12/918,678
Granted
May 24, 2016
Kind
B2
Abstract

The invention relates to methods for selectively converting a cysteine residue in a peptide or protein to the dehydroalanine (Dha) residue. The method also works on selenocysteine and substituted cysteine and selenocysteine residues, resulting in the Dha residue which may be converted to any natural or unnatural amino acid residue desired without the alteration of the remainder of the peptide or protein. The invention also allows ligation of a desired peptide at any point rather than at a point where there should be a naturally occurring cysteine, thereby allowing native chemical ligation to be used in the synthesis of peptides that do not contain cysteine. The methodology allows for the synthesis of very large peptides.

Claims (22)

1. A method for converting an unmodified cysteine residue of a peptide or protein to a dehydroalanine residue, the method comprising:

reacting an unmodified cysteine residue of the peptide or protein with a sulfonylhydroxylamine of formula:

wherein R is an electron withdrawing group, and wherein the method is performed at a pH of between 6 and 10, to convert the unmodified cysteine residue to a dehydroalanine residue.

2. The method of claim 1 wherein the sulfonylhydroxylamine is O-mesitylenesulfonylhydroxylamine.

3. The method of claim 1 wherein said reacting the unmodified cysteine residue with the sulfonylhydroxylamine takes place in a solution or suspension in a polar aprotic solvent.

4. The method of claim 3 wherein the polar aprotic solvent is dimethylformamide (DMF).

5. The method of claim 1 wherein said reacting the unmodified cysteine residue with sulfonylhydroxylamine takes place in the presence of a base.

6. The method of claim 5 wherein the base comprises a potassium carbonate or a phosphate buffer.

7. The method of claim 1 comprising a subsequent step of reacting the carbon-carbon double bond of the dehydroalanine residue.

8. The method of claim 7 wherein the step of reacting the carbon-carbon double bond is stereoselective.

9. The method of claim 7 wherein the carbon-carbon double bond of the dehydroalanine residue is reacted with a thiol to form a thioether derivatized peptide or protein.

10. The method of claim 7 wherein the carbon-carbon double bond of the dehydroalanine residue is reacted with an organoborate.

11. The method of claim 7 wherein the carbon-carbon double bond of the dehydroalanine residue is reacted with a organohalide in the presence of elemental zinc.

12. A method for producing a peptide or protein comprising the steps of:

a) joining two polypeptides by native chemical ligation, thereby forming a joined polypeptide; and

b) contacting the joined polypeptide with a sulfonylhydroxylamine to achieve conversion of an unmodified cysteine residue of the polypeptide to a dehydroalanine residue,

wherein the sulfonylhydroxylamine has the formula:

and wherein R is an electron withdrawing group, and wherein the method is performed at a pH of between 6 and 10.

13. The method of claim 12 wherein the unmodified cysteine residue is located at the site of native chemical ligation.

14. A method of converting an unmodified cysteine residue of a peptide or protein to a dehydroalanine residue, the method comprising:

reacting an unmodified cysteine residue of the peptide or protein with O-mesitylenesulfonylhydroxylamine, wherein the step of contacting takes place in dimethylformamide, and wherein the method is performed at a pH between 6 and 10, to convert the unmodified cysteine residue to a dehydroalanine residue.

15. The method of claim 1 , further comprising reversibly denaturing the peptide or protein before said reacting.

Assignments (6)
RELEASE OF SECURITY INTEREST IN PATENT COLLATERAL (049221/0673) Recorded Dec 19, 2024
From: JPMORGAN CHASE BANK, N.A.
To: CATALENT PHARMA SOLUTIONS, LLC; R.P. SCHERER TECHNOLOGIES, INC.; R.P. SCHERER TECHNOLOGIES, LLC; REDWOOD BIOSCIENCE, INC.
Reel/Frame 069751/0100 →
SUPPLEMENTAL SECURITY AGREEMENT Recorded May 20, 2019
From: R.P. SCHERER TECHNOLOGIES, LLC; CATALENT PHARMA SOLUTIONS, LLC; REDWOOD BIOSCIENCE, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 049221/0673 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2016
From: ISIS INNOVATION LIMITED
To: DAVIS, BENJAMIN G.
Reel/Frame 039554/0717 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2015
From: DAVIS, BENJAMIN G.
To: R.P. SCHERER TECHNOLOGIES, LLC
Reel/Frame 036838/0205 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2015
From: ISIS INNOVATION LIMITED
To: DAVIS, BENJAMIN G.
Reel/Frame 036838/0222 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2011
From: BERNARDES, GONCALO; CHALKER, JUSTIN; DAVIS, BENJAMIN
To: ISIS INNOVATION LIMITED
Reel/Frame 025808/0101 →